Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096958 | 1.00 | ACHE (0.38) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL20445035 | 0.90 | HRH3 (0.35) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL15164245 | 0.87 | KDM4E (0.47) | HRH3KDM4EALDH1A1MAOB | |
| SCHEMBL9278459 | 0.86 | ACHE (0.45) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL22544216 | 0.83 | KDM4E (0.36) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12385800 | 0.83 | KDM4E (0.36) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL10159852 | 0.80 | KDM4E (0.34) | HRH3KDM4E | |
| SCHEMBL12344636 | 0.80 | ACHE (0.36) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL18024245 | 0.80 | ACHE (0.36) | ACHECARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL15841179 | 0.80 | ACHE (0.36) | ACHECARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2022226667-A1 | SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9072696-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-8288540-B2 | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2012-10-16 | — | — | US | disclosed |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut INc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ACHE 4255/4885CARM1 1309/4885PRMT6 1183/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ACHE 2447/4885CARM1 1051/4885PRMT6 631/4885 |
| US-20110301145-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, LCK | ACHE 1279/4885CARM1 3358/4885PRMT6 1710/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ACHE 4300/4885CARM1 1030/4885PRMT6 970/4885 |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | ACHE 10/4885CARM1 1471/4885PRMT6 3257/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | ACHE 10/4885CARM1 1471/4885PRMT6 3257/4885 |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | FYN, LCK, ERBB2 | ACHE 3743/4885CARM1 1827/4885PRMT6 981/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | ACHE 1212/4885CARM1 1628/4885PRMT6 1486/4885 |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | ACHE 4047/4885CARM1 3836/4885PRMT6 3051/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | ACHE 3911/4885CARM1 4097/4885PRMT6 3118/4885 |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | ACHE 2132/4885CARM1 1345/4885PRMT6 649/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ACHE 3585/4885CARM1 712/4885PRMT6 849/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | ACHE 2557/4885CARM1 1251/4885PRMT6 494/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | ACHE 3585/4885CARM1 712/4885PRMT6 849/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ACHE 2447/4885CARM1 1051/4885PRMT6 631/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | ACHE 1081/4885CARM1 1134/4885PRMT6 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.